SNDL Gains 66.7% Stake in US Medical Cannabis Giant, Eyes Nasdaq Consolidation

For the healthcare sector, SNDL’s latest move is more than a corporate transaction—it’s a signal of the maturation of medical cannabis as a therapeutic category. With a 66.7% indirect equity stake in Parallel’s Florida, Texas, and Massachusetts operations, SNDL now has the ability to influence product quality, supply chain, and clinical protocols across licensed facilities that serve tens of thousands of patients. The planned consolidation into Nasdaq-listed financials could accelerate investment in evidence-based research and standardization, bringing medical cannabis closer to the standards expected of conventional pharmaceuticals.

On July 27, 2026, SNDL Inc. announced the completion of its acquisition of key assets from Parallel (Surterra Holdings), a vertically integrated U.S. cannabis operator with state-licensed operations in Florida, Texas, and Massachusetts. The transaction, structured as a strict foreclosure by secured creditors through a special-purpose entity (TransactionCo), gives SNDL indirect majority economic exposure equivalent to 66.7% of the equity and 69.4% of the debt of the acquired operations. SNDL plans to convert this indirect exposure into direct, consolidated holdings in the coming months, a move that would make it one of the first Nasdaq-listed companies with direct exposure to U.S. medical cannabis operations. The deal substantially reduces Parallel’s legacy debt load and provides SNDL, via its Sunstream Bancorp joint venture, a path to eventually consolidate U.S. operations on its financial statements—pending legal, regulatory, and accounting approvals.

“

By holding a 66.7% equity stake and a 69.4% debt position, SNDL effectively dominates the capital structure, giving it leverage to direct strategy and eventually consolidate.

The structure of this transaction is a creative workaround to the long-standing dilemma facing cannabis companies listed on major U.S. exchanges. Under federal law, cannabis remains a Schedule I controlled substance, and Nasdaq and the SEC have historically prohibited listed companies from directly touching plant-touching businesses in the U.S. SNDL, a Canadian company with a Nasdaq listing, has circumvented this by using a secured creditor foreclosure and an unconsolidated joint venture to gain economic benefits without direct control until regulatory clarity emerges. This parallels recent uplisting precedents—such as those by TerrAscend and Curaleaf—where companies have used complex organizational structures to gain exposure to U.S. cannabis while awaiting federal rescheduling or safe-harbor legislation.

The acquisition’s immediate impact is that SNDL now controls a portfolio of medical-only cannabis operations in three key states. Florida, with its robust medical program and population over 22 million, represents the crown jewel. Texas’s limited medical program is slowly expanding, and Massachusetts offers a mature adult-use market, though SNDL intends to focus on medical exposure to comply with Nasdaq requirements. By holding a 66.7% equity stake and a 69.4% debt position, SNDL effectively dominates the capital structure, giving it leverage to direct strategy and eventually consolidate. The debt reduction achieved through the foreclosure strengthens Parallel’s balance sheet, potentially improving cash flows and valuations ahead of a future uplisting or full consolidation.

For investors, the near-term catalyst is the expected conversion to direct consolidation. SNDL’s management has stated that it expects to complete this process within months, which would allow the company to report U.S. medical cannabis revenue directly, potentially re-rating the stock as it joins a small but growing club of Nasdaq-listed firms with U.S. plant-touching operations. The market is likely to scrutinize the company’s ability to navigate remaining regulatory hurdles, particularly the SEC’s willingness to allow consolidation under current CSA scheduling or pending rescheduling. The DEA’s ongoing review of cannabis rescheduling, following the HHS recommendation to move cannabis to Schedule III, could further accelerate the timeline.